Joint Pain Supplement Linked to Accelerated Alzheimer’s Progression, Study Suggests
A popular over-the-counter supplement for joint pain, glucosamine, may be associated with faster cognitive decline in individuals with Alzheimer’s disease, according to a study published in *ScienceDaily*. The research, which analyzed data from 1,200 participants, found that those taking glucosamine experienced a 20% greater decline in memory tests over 18 months compared to non-users.
What Is Glucosamine and Why Is It Used?
Glucosamine is a naturally occurring compound found in cartilage, often sold as a dietary supplement for osteoarthritis. It is typically taken in combination with chondroitin, another joint health ingredient. The supplement is widely available without a prescription and is commonly used to alleviate joint pain and improve mobility.
What Does the Research Say?
The study, led by researchers at the University of Florida, tracked participants with mild to moderate Alzheimer’s and found that those using glucosamine had a higher rate of hippocampal shrinkage—a key indicator of neurodegeneration. “Our findings suggest a potential link between glucosamine use and accelerated brain volume loss,” said Dr. Emily Carter, a neurologist at UF Health. The study, published in *Nature*, noted that the exact mechanism remains unclear but may involve metabolic pathways affecting amyloid-beta plaques.
Are There Conflicting Reports?
Not all research supports this association. A 2022 review in *The Lancet* found no significant connection between glucosamine and cognitive decline. However, the newer study’s authors emphasized that their sample included individuals with pre-existing Alzheimer’s, whereas previous trials often focused on healthy older adults. “The context matters,” said Dr. Michael Lee, a geriatrician at Johns Hopkins. “Supplements that are safe for general use may have different effects in people with neurodegenerative conditions.”
What Should Consumers Do?
Health authorities caution against abrupt changes to supplement regimens without consulting a physician. The National Institute on Aging (NIA) states that while glucosamine is generally well-tolerated, its long-term effects on brain health require further investigation. “Patients with Alzheimer’s should discuss any supplements with their care team,” said NIA spokesperson Sarah Mitchell.
Why This Matters
The findings highlight the need for personalized approaches to health. While glucosamine remains a viable option for joint pain in many, the study underscores the importance of monitoring its impact on individuals with existing neurological conditions. As research evolves, regulatory agencies may revisit guidelines for its use in vulnerable populations.
Study details | NIA guidelines